Reported Hearing Loss in Alzheimer’s Disease Is Associated With Loss of Brainstem and Cerebellar Volume

Daniel A. Llano1,2,3,4*, Susanna S. Kwok3, Viswanath Devanarayan5,6, and The Alzheimer’s Disease Neuroimaging Initiative (ADNI)†

1 Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL, United States, 2 Carle Neuroscience Institute, Urbana, IL, United States, 3 Carle Illinois College of Medicine, Urbana, IL, United States, 4 Beckman Institute for Advanced Science and Technology, Urbana, IL, United States, 5 Eisai Inc., Woodcliff Lake, NJ, United States, 6 Department of Mathematics, Statistics and Computer Science, University of Illinois at Chicago, Chicago, IL, United States

Multiple epidemiological studies have revealed an association between presbycusis and Alzheimer’s Disease (AD). Unfortunately, the neurobiological underpinnings of this relationship are not clear. It is possible that the two disorders share a common, as yet unidentified, risk factor, or that hearing loss may independently accelerate AD pathology. Here, we examined the relationship between reported hearing loss and brain volumes in normal, mild cognitive impairment (MCI) and AD subjects using a publicly available database. We found that among subjects with AD, individuals that reported hearing loss had smaller brainstem and cerebellar volumes in both hemispheres than individuals without hearing loss. In addition, we found that these brain volumes diminish in size more rapidly among normal subjects with reported hearing loss and that there was a significant interaction between cognitive diagnosis and the relationship between reported hearing loss and these brain volumes. These data suggest that hearing loss is linked to brainstem and cerebellar pathology, but only in the context of the pathological state of AD. We hypothesize that the presence of AD-related pathology in both the brainstem and cerebellum creates vulnerabilities in these brain regions to auditory deafferentation-related atrophy. These data have implications for our understanding of the potential neural substrates for interactions between hearing loss and AD.

Keywords: presbycusis, cerebellum, auditory, brainstem, dementia, Alzheimer’s

INTRODUCTION

The increase in human lifespan afforded by modern medicine has revealed an emerging health crisis: the growing numbers of individuals with aging-related hearing loss (ARHL) and Alzheimer’s Disease (AD). These disorders strip away patients’ abilities to connect with their loved ones, either via verbal communication or by relating shared experiences. The number of individuals with these disorders is expected to grow because of the aging of our society. By 2050 it is estimated that approximately 1.5 billion people worldwide will be over the age of 65 (He et al., 2016), and approximately 40% of them will have ARHL (Nash et al., 2011) and 10% will have AD (Hebert et al., 2013).
A series of recent epidemiological studies has shown that elderly individuals with ARHL have a higher risk of developing aging-related cognitive decline, mild cognitive impairment (MCI) or AD (Lin et al., 2011a,b,c, 2013; Panza et al., 2015; Golub et al., 2017; Thomson et al., 2017; Ford et al., 2018). Across these studies, the increase in risk of developing cognitive impairment is approximately 50–100% above baseline, and this risk increase exists despite controlling for potentially confounding variables such as age, apolipoprotein E genotype and cardiovascular risk factors. In addition, hearing loss (HL) in AD is not only observed in the auditory periphery. In fact, patients with AD show evidence of more central, rather than peripheral, auditory dysfunction, though both are affected in this disorder (reviewed in Swords et al., 2018).

The finding that ARHL and AD are epidemiologically linked raises several questions with therapeutic implications. For example, it is not yet known if AD and ARHL are causally associated, or if a third, as yet unidentified factor, mediates this relationship. If they are causally linked, then efforts to mitigate one (e.g., aggressive early treatment of ARHL) may lower the incidence of the other. Currently less than 20% of individuals that could benefit from hearing aids use them (Popelka et al., 1998; Chien and Lin, 2012), suggesting that there is a large potential pool of individuals that could benefit from early intervention to limit the impact of ARHL, and therefore potentially lower the incidence of AD. Consistent with the potential benefits of early and aggressive intervention to treat ARHL is the finding that cochlear implantation may enhance overall cognitive function in elderly patients with hearing loss (Utoomprurkporn et al., 2020; Knopke et al., 2021; Mertens et al., 2021). The animal literature is generally supportive of the finding that induction of HL can cause more global cognitive dysfunction, but does not generally lead to a progressive degenerative phenotype (reviewed by Nadhimi and Llano, 2020). Alternatively, if ARHL and AD are linked by a third factor (e.g., brain inflammation, oxidative stress, metabolic dysfunction, etc.), then aggressive treatment of that third factor would be required to limit the impact of both disorders. Supporting this latter hypothesis is the recent finding of an interaction between ARHL, AD and serum phosphatidylcholine levels (Llano et al., 2020). Low blood phosphatidylcholine levels are an indicator of oxidative stress and inflammation (Jacobsson et al., 1990; Kurutas, 2015), and these levels were lowered in individuals with ARHL and AD, but not in controls (Llano et al., 2020), suggesting that the relationship between ARHL and AD may be mediated by factors common to both disorders. If a mediating factor is present, it is not yet clear how that factor impacts the brain or which brain regions may be most vulnerable.

Therefore, in the current study, we examined the anatomical substrates that may link AD and HL. Specifically, we examined volumetric magnetic resonance imaging (MRI) data from cognitively normal controls, MCI subjects and AD subjects with or without reports of HL using a publicly available dataset. We found several hindbrain regions (brainstem, bilateral cerebellum cortex and cerebellar white matter) that showed volume reductions in subjects with both reported HL and AD, but not in cognitively normal control or MCI subjects. This interaction between reported HL, AD diagnostic state and hindbrain volume loss suggests that the presence of AD pathology may reveal pathological interactions between the peripheral auditory system and structures in the early central auditory system. It is not yet known if an additional factor may explain these interactions.

**MATERIALS AND METHODS**

**Database**

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database¹. The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For up-to-date information, see www.adni-info.org. This study was registered under clinicaltrials.gov under ClinicalTrials.gov Identifier: NCT00106899. The study was conducted across multiple clinical sites and was approved by the Institutional Review Boards of all of the participating institutions. Informed written consent was obtained from all participants at each site. The following individual ethics boards approved the study: Albany Medical College Institutional Review Board, Boston University Medical Campus Institutional Review Board (BU IRB), Butler Hospital Institutional Review Board, Cleveland Clinic Institutional Review Board, Columbia University Institutional Review Board, Dartmouth-Hitchcock Medical Center Committee for the Protection of Human Subjects, Duke University Health System Institutional Review Board, Emory University Institutional Review Board Georgetown University Institutional Review Board, Human Investigation Committee Yale University School of Medicine, Human Subjects Committee, University of Kansas Medical Center, Indiana University Institutional Review Board, Research Compliance Administration, Institutional Review Board of Baylor College of Medicine, Institutional Review Board of the Mount Sinai School of Medicine, Johns Hopkins University School of Medicine Institutional Review Boards, Lifespan—Rhode Island Hospital Institutional Review Board, Mayo Clinic Institutional Review Board, Nathan Kline Institute Rockland Psychiatric Center Institutional Review Board (NKI RPC IRB), New York University Langone Medical Center School of Medicine, Institutional Review Board Human Research Program, Northwestern University Institutional Review Board Office, Office of the Washington University School of Medicine IRB (OWUMC IRB), Oregon Health and Science University Institutional Review Board, Partners Human Research Committee, Research Ethics Board Jewish General Hospital, Research Ethics Board Sunnybrook Health Sciences Centre, Roper St. Francis Institutional Review Board, Rush University Medical Center Institutional Review Board.

¹adni.loni.usc.edu
Subjects having a hearing complaint are labeled in this study et al. (2020) and were selected prior to the data being seen. Search terms are identical to those used by Xu et al. (2019) and Llano et al., 2020), we used subjective hearing loss complaints found in the database. Similar to previous reports (Xu et al., 2019; Llano and Hochberg, 1995). MRI features with q-value < 0.1 were considered as statistically significant, which is aligned with published recommendations (Efron, 2007). In addition, we apply a criterion of an absolute value of Cohen’s D to be greater than 0.2 to ensure sufficient magnitudes of the statistically significant effects (Sawilowsky, 2009).

For the regional MRI features that are significantly different (q < 0.1) at baseline between RHL and NHL, the rate of change over time (slope) of the composite sum of these features were compared between the RHL and NHL subjects for each diagnostic group separately via a mixed effects model. In this model, Time (month) since first visit was included as a continuous covariate, RHL vs. NHL and the interaction of Time with RHL and NHL were included as fixed effects, and subjects were included as random effect. The quadratic trend of Time was also included and retained in the model if it was significant. The interaction effect from this model was used to assess whether the slope of the composite MRI feature over time was greater in RHL subjects relative to the NHL subjects, with the one-sided p-value < 0.05 used as the criteria for statistical significance. All analyses were carried out using R version 4.0.5 (R Development Core Team, 2014).

RESULTS

Demographics
Data were obtained from a total of 725 subjects, of whom 229 were age-matched cognitively normal, 308 had MCI and 188 as “reported hearing loss” or RHL. Other subjects are listed as “non-reported hearing loss” or NHL.

Imaging
MRI methods for ADNI have been reported previously in detail (Jack et al., 2008). In brief, scans at 1.5 or 3T were obtained across multiple sites and scanners (General Electric, Philips, Siemens). T1-weighted images were obtained using MP-RAGE (Magnetization Prepared Rapid Acquisition Gradient Echo) sequences and were obtained at multiple timepoints for individual subjects. Segmentation of brain regions was done using FreeSurfer software¹ (Dale et al., 1999; Fischl et al., 1999).

Statistical Methods
The effect of each of the 257 regional brain MRI features (volume/area/thickness) on RHL in AD, MCI and cognitively normal subjects was assessed via analysis of covariance (ANCOVA) after adjusting for gender and age as covariates. Subjects with absolute value of studentized residuals from this model exceeding 3 were identified as outliers and excluded from further analysis. The summary measures reported from this analysis include the fold change of the regional MRI feature for the subjects with RHL relative to the subjects with NHL, Cohen’s D statistic, covariates-adjusted significance (p-value), an estimate of the false discovery rate, q-value (Benjamini and Hochberg, 1995). MRI features with q-value < 0.1 were considered as statistically significant, which is aligned with published recommendations (Efron, 2007). In addition, we apply a criterion of an absolute value of Cohen’s D to be greater than 0.2 to ensure sufficient magnitudes of the statistically significant effects (Sawilowsky, 2009).

Clinical Diagnosis and Hearing Loss Assessment
AD was diagnosed using NINCDS/ADRDA criteria for probable AD (McKhann et al., 1984). MCI patients had a memory complaint, an abnormal score on the Logical Memory II subscale from the Wechsler Memory Scale, an MMSE score between 24 and 30 and a Clinical Dementia Rating scale score of 0.5. Cognitively normal subjects did not have a memory complaint, had a normal score on the Logical Memory II subscale and had a Clinical Dementia Rating scale score of zero. Hearing was not systematically measured in the ADNI database. Similar to previous reports (Xu et al., 2019; Llano et al., 2020), we used subjective hearing loss complaints found in the following datasheets: ADSXLIST.csv, BLSCHECK.csv, INITHEALTH.csv, MEDHIST.csv, NEUROEXM.csv, PHYSICAL.csv, RECBLLOG.csv, RECMHIST.csv. We used the search terms “hear,” “auditory,” “ear,” “deaf,” “presbycusis,” and “HOH (hard of hearing)” and eliminated those reports that were clearly not related to ARHL (e.g., skin cancer on ear, earwax, etc.), as well as eliminating entries that referred to tinnitus without mention of hearing loss as well as central processing disorder, and eliminated duplicates. These search terms are identical to those used by Xu et al. (2019) and Llano et al. (2020) and were selected prior to the data being seen. Subjects having a hearing complaint are labeled in this study

¹http://adni.loni.usc.edu/methods/documents/mri-protocols/
²https://surfer.nmr.mgh.harvard.edu/
TABLE 1 | Demographics.

| Gender | N | RHL | NHL | RHL | NHL | RHL | NHL | RHL | NHL | RHL | NHL | RHL | NHL | RHL | NHL | RHL | NHL | RHL |
|--------|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Female | 82 | 28  | 84  | 22* | 77  | 13* | 69  | 29  | 98  | 27  | 77  | 13* | 69  | 29  | 98  | 27  | 77  | 13* | 69  | 29  |
| Male   | 80 | 39  | 132 | 70  | 69  | 29  | 98  | 27  | 77  | 13* | 69  | 29  | 98  | 27  | 77  | 13* | 69  | 29  | 98  | 27  |

Age (years): Mean (SD) 75.6 (4.9) 76.5 (5.2) 73.8 (7.5) 77.8* (6.1) 74.6 (7.7) 77.6* (5.9)

Education (years): Mean (SD) 15.8 (2.9) 16.6 (2.7) 15.6 (3) 15.8 (2.9) 14.8 (2.9) 14.5 (3.8)

MMSE: Mean (SD) 29.1 (1) 29.1 (1) 27 (1.7) 27 (1.8) 23.5 (1.9) 22.8 (2.4)

Values are mean (SD). RHL, reported hearing loss. NHL, no reported hearing loss. *p < 0.05 comparing RHL to NHL.

TABLE 2 | Top 20 markers, based on p and q-values, differentiating RHL from NHL in cognitively normal subjects, corrected for age and gender.

| Rank | Marker ID | Marker name | Ratio RHL/NHL | CohensD | p (Marker) | q (Marker) |
|------|-----------|-------------|---------------|----------|------------|------------|
| 1    | ST60TA    | Cortical Thickness Average of LeftTemporalPole      | 1.04        | 0.52     | 0.0007     | 0.1730     |
| 2    | ST55SV    | Volume (WM Parcellation) of CorpusCallosumMidPosterior | 1.07        | 0.29     | 0.0053     | 0.6840     |
| 3    | ST111SV   | Volume (WM Parcellation) of LeftAccumbensArea       | 1.09        | 0.45     | 0.0178     | 0.7650     |
| 4    | ST45SV    | Volume (WM Parcellation) of CorpusCallosumMidAnterior | 1.07        | 0.39     | 0.0202     | 0.7650     |
| 5    | ST103TA   | Cortical Thickness Average of RightParahippocampal   | 1.04        | 0.39     | 0.0209     | 0.7650     |
| 6    | ST128SV   | Volume (WM Parcellation) of WMHypointensities      | 0.92        | −0.15    | 0.0414     | 0.7650     |
| 7    | ST68SV    | Volume (WM Parcellation) of CorpusCallosumPosterior | 1.05        | 0.31     | 0.0427     | 0.7650     |
| 8    | ST112SV   | Volume (WM Parcellation) of Putamen                | 1.03        | 0.28     | 0.0467     | 0.7650     |
| 9    | ST73CV    | Volume (Cortical Parcellation) of RightCaudalAnteriorCingulate | 1.03 | 0.14 | 0.0481 | 0.7650 |
| 10   | ST59CV    | Volume (Cortical Parcellation) of LeftSupramarginal | 1.03        | 0.19     | 0.0483     | 0.7650     |
| 11   | ST24CV    | Volume (Cortical Parcellation) of LeftEntorhinal    | 1.05        | 0.25     | 0.0525     | 0.7650     |
| 12   | ST75SV    | Volume (WM Parcellation) of CSF                     | 0.91        | −0.45    | 0.0539     | 0.7650     |
| 13   | ST113SA   | Surface Area of RightRostralAnteriorCingulate       | 1.07        | 0.29     | 0.0567     | 0.7650     |
| 14   | ST91CV    | Volume (Cortical Parcellation) of RightInferiorTemporal | 1.01 | 0.08 | 0.0649 | 0.7650 |
| 15   | ST44CV    | Volume (Cortical Parcellation) of LeftParahippocampal | 1.07        | 0.49     | 0.0657     | 0.7650     |
| 16   | ST43SA    | Surface Area of LeftParacentral                     | 1.02        | 0.2      | 0.0667     | 0.7650     |
| 17   | ST12SV    | Volume (WM Parcellation) of LeftAmygdala           | 1.03        | 0.23     | 0.0675     | 0.7650     |
| 18   | ST99CV    | Volume (Cortical Parcellation) of RightMiddleTemporal | 1.04 | 0.24 | 0.0697 | 0.7650 |
| 19   | ST72TA    | Cortical Thickness Average of RightBanksts          | 1.01        | 0.15     | 0.0730     | 0.7650     |
| 20   | ST102TA   | Cortical Thickness Average of RightParacentral      | 1.02        | 0.17     | 0.0752     | 0.7650     |

WM, white matter; CSF, cerebrospinal fluid.

Impact of Reported Hearing Loss in Cognitively Normal and Mild Cognitive Impairment Subjects

257 brain regions were examined and compared between cognitively normal subjects with or without RHL. After adjusting for age and sex, and controlling for false discovery rates, none of the brain regions demonstrated differences between RHL and NHL subjects. Similarly for MCI subjects, there were no differences in regional brain volumes between hearing RHL and NHL subjects (Tables 2, 3).

Impact of Hearing Loss in Alzheimer’s Disease Subjects

After adjusting for age and sex, and after controlling for multiple comparisons, six brain regions were found to be significantly

had AD. Among these subjects, 67 cognitively normal (29.2%), 92 MCI (29.8%) and 42 AD (22.3%) subjects reported HL. The proportions of subjects reporting HL was similar in all three groups (p > 0.05, Chi-Square). RHL subjects were on average older than NHL subjects among those that were diagnosed as MCI or AD (p < 0.05, Wilcoxon), but not significantly different among cognitively normal subjects. RHL subjects were more likely to be men than NHL subjects among those that were diagnosed as either MCI or AD (p < 0.05, Chi-Square), but not significantly different among the cognitively normal subjects. RHL and NHL subjects did not differ significantly with respect to Education level, apolipoprotein E4 (ApoE4) and Mini-mental status exam (MMSE) in all three diagnostic groups (cognitively normal, MCI and AD). See Table 1 for further details. Given the differences in age and sex in RHL vs. NHL subjects listed above, all subsequent analyses were adjusted for age and sex.
TABLE 3 | Top 20 markers, based on \( p \) and \( q \)-values, differentiating HL from NHL in MCI subjects, corrected for age and gender.

| Rank | Marker ID | Marker name                                      | Ratio RHL/NHL | CohensD | \( p \) (Marker) | \( q \) (Marker) |
|------|-----------|--------------------------------------------------|---------------|---------|----------------|----------------|
| 1    | ST106TA   | Cortical Thickness Average of RightParsTriangularis | 1.02          | 0.20    | 0.0019         | 0.4860         |
| 2    | ST44SA    | Surface Area of LeftParahippocampal               | 0.95          | –0.38   | 0.0060         | 0.5720         |
| 3    | ST45TA    | Cortical Thickness Average of LeftParsOpercularis | 1.01          | 0.07    | 0.0088         | 0.5720         |
| 4    | ST36TA    | Cortical Thickness Average of LeftLateralOrbitofrontal | 1.00          | 0.05    | 0.0125         | 0.5720         |
| 5    | ST121TA   | Cortical Thickness Average of RightTransverseTemporal | 1.05          | 0.30    | 0.0144         | 0.5720         |
| 6    | ST72TA    | Cortical Thickness Average of RightBankssts       | 1.01          | 0.15    | 0.0155         | 0.5720         |
| 7    | ST166SA   | Surface Area of RightParsTriangularis             | 0.95          | –0.29   | 0.0156         | 0.5720         |
| 8    | ST104TA   | Cortical Thickness Average of RightParsOpercularis | 1.01          | 0.09    | 0.0244         | 0.7510         |
| 9    | ST102CV   | Volume (Cortical Parcellation) of RightParacentral | 1.02          | 0.12    | 0.0265         | 0.7510         |
| 10   | ST68SV    | Volume (WM Parcellation) of Non-WMHypointensities | 0.85          | –0.23   | 0.0382         | 0.7510         |
| 11   | ST168SV   | Volume (WM Parcellation) of LeftCaudate           | 0.97          | –0.21   | 0.0389         | 0.7510         |
| 12   | ST84CV    | Volume (Cortical Parcellation) of RightFrontalPole | 1.03          | 0.13    | 0.0431         | 0.7510         |
| 13   | ST48SA    | Surface Area of LeftPericalcarine                 | 0.96          | –0.22   | 0.0457         | 0.7510         |
| 14   | ST25CV    | Volume (Cortical Parcellation) of LeftFrontalPole  | 1.01          | 0.03    | 0.0501         | 0.7510         |
| 15   | ST75SV    | Volume (WM Parcellation) of RightCaudate          | 0.98          | –0.13   | 0.0517         | 0.7510         |
| 16   | ST110TA   | Cortical Thickness Average of RightPrecentral     | 0.99          | –0.09   | 0.0524         | 0.7510         |
| 17   | ST23TA    | Cortical Thickness Average of LeftCuneus           | 1.01          | 0.08    | 0.0536         | 0.7510         |
| 18   | ST73TA    | Cortical Thickness Average of RightCaudalAnteriorCingulate | 1.01          | 0.10    | 0.0542         | 0.7510         |
| 19   | ST45SA    | Surface Area of LeftRostralAnteriorCingulate      | 0.95          | –0.24   | 0.0565         | 0.7510         |
| 20   | ST50SA    | Surface Area of LeftPosteriorCingulate            | 0.99          | –0.04   | 0.0595         | 0.7510         |

WM, white matter.

FIGURE 1 | Volcano plot showing the Cohen’s D value vs. \(-\log_{10}(q\)-value\) for all markers for AD subjects. Six markers met criteria for having a \( q \)-value of less than 0.1 \((-\log_{10}(q\)-value\) > 1) and having a Cohen’s D of above 0.2. Marker codes are shown. Full marker names can be found in Table 4.

smaller in AD subjects with RHL compared to NHL subjects and had Cohen’s D values above 0.2. These brain regions were the volume of left and right cerebellar white matter, volume of the brain stem, volume of left ventral diencephalon, and the volume of left and right cerebellar cortex (see Figure 1 for volcano plot). Thus, five out of the six regions that differentiated reports of hearing loss from non-reported hearing loss were either in the cerebellum or brainstem, and all regions showed smaller volumes with an average effect size of \(-0.61 (0.33 SD)\) (see Table 4 and Figure 2 for boxplots).

For the six brain regions listed above that were significantly smaller in AD subjects with RHL, interaction of reported
TABLE 4 | Top 20 markers, based on p and q-values, differentiating HL from NHL in AD subjects, corrected for age and gender.

| Rank | Marker ID | Marker name | Ratio RHL/NHL | CohensD | p (Marker) | q (Marker) |
|------|-----------|-------------|---------------|---------|------------|------------|
| 1    | ST18SV    | Volume (WM Parcellation) of LeftCerebellumWM | 0.87         | −1.01   | 0.0000     | 0.0001     |
| 2    | ST77SV    | Volume (WM Parcellation) of RightCerebellumWM | 0.87         | −1.03   | 0.0000     | 0.0015     |
| 3    | ST15SV    | Volume (WM Parcellation) of Brainstem      | 0.94         | −0.52   | 0.0002     | 0.0130     |
| 4    | ST63SV    | Volume (WM Parcellation) of LeftVentralDiencephalon | 0.94         | −0.50   | 0.0010     | 0.0613     |
| 5    | ST17SV    | Volume (WM Parcellation) of LeftCerebellumCortex | 0.97         | −0.26   | 0.0012     | 0.0622     |
| 6    | ST76SV    | Volume (WM Parcellation) of RightCerebellumCortex | 0.97         | −0.35   | 0.0015     | 0.0642     |
| 7    | ST20SV    | Volume (WM Parcellation) of LeftCerebralWM | 0.95         | −0.35   | 0.0029     | 0.1040     |
| 8    | ST32SA    | Surface Area of LeftInferiorLateralVentricle | 0.94         | −0.36   | 0.0039     | 0.1260     |
| 9    | ST124SV   | Volume (WM Parcellation) of RightVentralDC | 0.96         | −0.41   | 0.0053     | 0.1520     |
| 10   | ST36CV    | Volume (Cortical Parcellation) of LeftLateralOrbitofrontal | 0.95         | −0.44   | 0.0080     | 0.2010     |
| 11   | ST102SA   | Volume (WM Parcellation) of RightParacentral | 0.96         | −0.30   | 0.0086     | 0.2010     |
| 12   | ST52CV    | Volume (Cortical Parcellation) of LeftPrecuneus | 0.96         | −0.19   | 0.0114     | 0.2270     |
| 13   | ST11SV    | Volume (WM Parcellation) of LeftAccumbensArea | 0.90         | −0.35   | 0.0115     | 0.2270     |
| 14   | ST30SV    | Volume (WM Parcellation) of LeftInferiorLateralVentricle | 1.43         | 0.69    | 0.0198     | 0.3630     |
| 15   | ST102CV   | Volume (Cortical Parcellation) of RightParacentral | 0.99         | −0.08   | 0.0248     | 0.3820     |
| 16   | ST26SA    | Surface Area of LeftFusiform                | 0.98         | −0.12   | 0.0261     | 0.3820     |
| 17   | ST52SA    | Surface Area of LeftPrecuneus               | 0.99         | −0.08   | 0.0266     | 0.3820     |
| 18   | ST32CV    | Volume (Cortical Parcellation) of LeftInferiorLateralVentricle | 0.99         | −0.05   | 0.0279     | 0.3820     |
| 19   | ST59CV    | Volume (Cortical Parcellation) of LeftSupramarginal | 0.97         | −0.22   | 0.0312     | 0.3820     |
| 20   | ST50SA    | Surface Area of LeftPosteriorCingulate       | 0.96         | −0.28   | 0.0317     | 0.3820     |

Rows shaded in light gray met the q < 0.1 threshold. WM, white matter; DC, diencephalon.

Hearing status and disease diagnosis was assessed via analysis of covariance, after adjusting for age and gender. The interaction effect was significant in all of these brain regions, except for cerebellar cortex. However, post hoc evaluation of this interaction effect revealed that all these brain regions had significantly lower volume/area in only the AD subjects with RHL (p < 0.05), but not among the MCI and cognitively normal subjects. This relationship was not investigated further for ApoE4 carriers and non-carriers due to inadequate sample size of subgroups.

We then studied the rate of change over time of the six regional MRI features that were significantly different at baseline between RHL and NHL in AD patients. We took a composite sum of these features and compared their slopes over time between RHL and NHL in the cognitively normal, MCI and AD subjects separately. While this analysis revealed a greater rate of atrophy over time in the cognitively normal, MCI and AD subjects with RHL, this effect was only observed in the cognitively normal and did not reach significance in the MCI subjects (p = 0.029 and 0.084, respectively, Table 5). This finding implies that the greater atrophy seen in these brain regions at baseline in the AD subjects with RHL is a reflection of the faster atrophy over time in these brain regions in the cognitively normal subjects with RHL.

In addition, given the adverse cognitive impacts of psychotropics and use of anticholinergic drugs is not likely to be responsible for differences in brain volumes observed in the current study.

**DISCUSSION**

In the current study, 257 brain regions were measured in 229 cognitively normal subjects, 308 MCI subjects and 188 AD subjects, and these subjects were further divided into those with self-report of hearing loss (RHL) or with no self-report of hearing loss (NHL). RHL was not associated with differences in brain volumes or surface areas in cognitively normal control or MCI subjects. In contrast, bilateral cerebellar volumes and brainstem volume were diminished in AD subjects with RHL compared to the NHL group. Two of these six brain regions (left and right cerebellar white matter) had effect sizes greater than 1.0, indicating a strong effect of reported hearing loss (Sawilowsky, 2009). A statistically significant interaction was found between these brain volumes, disease diagnosis and the presence of RHL. A composite score of all six brain regions also showed an average faster rate of decline over time in cognitively normal subjects with RHL compared to the NHL group. These data suggest that hearing impairment is associated with accelerated volume loss in the brainstem and cerebellum in AD subjects, which are both regions that receive substantial auditory input. These findings are discussed below.

**Limitations in the Study**

This study employed subjective reports of HL, rather than objectively measured HL, such as can be measured with a pure-tone audiogram or auditory brainstem response. Use of subjective
measures was required because hearing was not objectively measured in this dataset. Previous work has shown that subjective hearing loss shows an approximately 65–77% concordance rate with objectively measured hearing loss (Kamil et al., 2015). Thus, it is possible that subjects in the NHL group, in fact had some degree of loss of hearing, or vice-versa. The likely net impact of using subjective, rather than objective, metrics of hearing loss is to dilute the impact of loss of hearing on the differences between the measured brain volumes and surface areas in the two groups. Despite this necessary uncertainty in group assignment, previous studies of the ADNI dataset have used the same approach and revealed RHL-related differences across a range of biomarkers (Xu et al., 2019; Llano et al., 2020). These data suggest the impact of HL is robust to the diluting effect of assignment ambiguity, but that future biomarker studies in dementing illness should consider incorporation of objective measures of hearing impairment into their array of clinical tests.

**Implications of This Study**

Similar to previous work (Xu et al., 2019), when subjects are stratified by disease state, no relationship was observed between reports of HL and hippocampal volume, which has traditionally been inversely associated with AD disease state (Gosche et al., 2002). With the majority of literature focusing on shared temporal lobe dysfunction, AD and ARHL together have not been described in the context of shared brainstem and cerebellar

**TABLE 5** Slopes of decline of composite volume score in NHL vs. RHL subjects, starting at cognitively normal, MCI or AD state.

| Composite of six significant regional features between RHL and NHL in AD subjects at baseline | Slope of NHL (mm³/year) | Slope of HL (mm³/year) | Slope difference (RHL-NHL) | p-value for Slope of RHL > NHL |
|---|---|---|---|---|
| Cognitively normal | -86.57 | -100.02 | -13.44 | 0.029 |
| MCI | -114.16 | -124.58 | -10.43 | 0.084 |
| AD | -88.27 | -98.13 | -9.87 | 0.341 |

**FIGURE 2** Box plots showing the median, first and third quartiles of the distributions, demonstrating differences in volumes of the six brain regions in AD subjects that significantly differentiated RHL from NHL subjects. WM, white matter.
temporal cortical regions receive less direct synaptic input from the auditory periphery than brainstem and certain regions of the cerebellum, such as the paraflocculus, they may be less prone to show deafferentation-related changes. It is also possible that floor effects may be present in our AD population such that AD patients may have atrophy of these brain regions beyond a degree which may be differentiated based on HL.

CONCLUSION

Thus, in the current study, we observed that in the context of AD, RHL was associated with lowered volumes of the brainstem and cerebellum, as well as faster rates of declines in these regions. These data suggest that pathological changes that occur in the brainstem and cerebellum in AD increase the vulnerability of these regions to auditory deafferentation-related pathology. Given the growing literature suggesting that ARHL may predispose to AD, it is possible that acoustic deafferentation may trigger brainstem pathology. Given early pathological changes that occur in the brainstem in AD (Rüb et al., 2001; Simic et al., 2009), it is possible that HL may lead to pathological reorganization at the level of the brainstem and cerebellum, which, in vulnerable patients, may lead to broader AD pathology. Overall, our understanding of the cerebellum as it relates to either hearing or AD remains limited, and the analysis of both pathologies as they relate to changes in cerebellar volume was described for the first time by this study. In addition, the number of subjects in the AD with RHL group was relatively small (n = 42), and too small to parse effects of other important factors such as ApoE4 status. Thus, future work, particularly large-scale studies where both hearing levels and MRI volumes are quantitatively measured, will be needed to examine the relationship between hearing impairment and brain volume changes more closely.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: http://adni.loni.usc.edu/.

ETHICS STATEMENT

The study was conducted across multiple clinical sites and was approved by the Institutional Review Boards of all of the participating institutions. Informed written consent was obtained from all participants at each site. The following individual ethics boards approved the study: Albany Medical College Institutional Review Board, Boston University Medical Campus Institutional Review Board (BU IRB), Butler Hospital Institutional Review Board, Cleveland Clinic Institutional Review Board, Columbia University Institutional Review Board, Dartmouth-Hitchcock Medical Center Committee for the Protection of Human Subjects, Duke University Health System Institutional Review Board, Emory University Institutional Review Board Georgetown University Institutional Review Board, Human Investigation Committee Yale University
School of Medicine, Human Subjects Committee, University of Kansas Medical Center, Indiana University Institutional Review Board, Research Compliance Administration, Institutional Review Board of Baylor College of Medicine, Institutional Review Board of the Mount Sinai School of Medicine, Johns Hopkins University School of Medicine Institutional Review Boards, Lifespan—Rhode Island Hospital Institutional Review Board, Mayo Clinic Institutional Review Board, Nathan Kline Institute Rockland Psychiatric Center Institutional Review Board (NKI RPC IRB), New York University Langone Medical Center School of Medicine, Institutional Review Board Human Research Program, Northwestern University Institutional Review Board Office, Office of the Washington University School of Medicine IRB (OWUMC IRB), Oregon Health and Science University Institutional Review Board, Partners Human Research Committee, Research Ethics Board Jewish General Hospital, Research Ethics Board Sunnybrook Health Sciences Centre, Roper St. Francis Institutional Review Board, Rush University Medical Center Institutional Review Board, Stanford University, Administrative Panel on Human Subjects in Medical Research, The Ohio State University Institutional Review Board, The University of Texas Southwestern Medical Center Institutional Review Board, UCLA Office of the Human Research Protection Program Institutional Review Board, UCSD Human Research Protections Program, University Hospitals Case Medical Center Institutional Review Board, University of Alabama at Birmingham Institutional Review Board, University of British Columbia, Clinical Research Ethics Board (CREB), University of California Davis Office of Research IRB Administration, University of California Irvine Office Of Research Institutional Review Board (IRB), University of California San Francisco Committee on Human Research (CHIR), University of Iowa Institutional Review Board, University of Kentucky Office of Research Integrity, University of Michigan Medical School Institutional Review Board (IRBMED), University of Pennsylvania Institutional Review Board, University of Pittsburgh Institutional Review Board, University of Rochester Research Subjects Review Board (RSRB), University of South Florida Division of Research Integrity & Compliance, University of Southern California Health Science Campus Institutional Review Board, University of Western Ontario Research Ethics Board for Health Sciences Research Involving Human Subjects (HSREB), University of Wisconsin Health Sciences Institutional Review Board, Wake Forest University Institutional Review Board, Weill Cornell Medical College Institutional Review Board, Western Institutional Review Board and Western University Health Sciences Research Ethics Board. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

DL and VD conceived of the project. DL, SK, and VD wrote the manuscript. VD did data analysis. All authors contributed to the article and approved the submitted version.

FUNDING

Data collection and sharing for this project were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroMmune; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Mesoscale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

REFERENCES

Ackermann, H. (2008). Cerebellar contributions to speech production and speech perception: psycholinguistic and neurobiological perspectives. Trends Neurosci. 31, 265–272. doi:10.1016/j.tins.2008.02.011

Aitkin, L., and Boyd, J. (1978). Acoustic input to the lateral pontine nuclei. Hear. Res. 1, 67–77. doi:10.1016/0378-5955(78)90010-2

Aitkin, L. M., and Boyd, J. (1975). Responses of single units in cerebellar vermis of the cat to monaural and binaural stimuli. J. Neurophysiol. 38, 418–429. doi:10.1152/jn.1975.38.2.418

Beers, M. H. (1997). Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch. Intern. Med. 157, 1531–1536. doi:10.1001/archinte.157.14.1531

Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289–300. doi:10.1111/j.2517-6161.1995.tb02031.x

Bielachowsky, M. (1911). Zur kenntnis der alzheimerschen krankheit (präsenilen Demenz mit Herdsymptomen). J. Psychol. Neurol. 18, 273–292.

Braak, H., Braak, E., Bohl, J., and Lang, W. (1989). Alzheimer’s disease: amyloid plaques in the cerebellum. J. Neurol. Sci. 93, 277–287.

Chien, W., and Lin, F. R. (2012). Prevalence of hearing aid use among older adults in the United States. Arch. Intern. Med. 172, 292–293. doi:10.1001/archinternmed.2011.1408

Dale, A. M., Fischl, B., and Sereno, M. I. (1999). Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage 9, 179–194.
Devita, M., Alberti, F., Fagnani, M., Fabio, M., Aea, E., Sergi, G., et al. (2021). Novel insights into the relationship between cerebellum and dementia: a narrative review as a toolkit for clinicians. *Ageing Res. Rev.* 70:101389. doi: 10.1016/j.arr.2021.101389

Efron, B. (2007). Size, power and false discovery rates. *Ann. Statist.* 35, 1351–1377.

Ehrenberg, A., Nguyen, A., Theofilis, P., Dunlop, S., Suemoto, C., Albo, A., et al. (2017). Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer’s disease. *Neuropathol. Appl. Neurobiol.* 43, 393–408. doi: 10.1111/nan.12387

Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., and Waller, J. L. (2011a). Hearing loss and cognition in the Baltimore Longitudinal Study of Aging. *Arch. Neurol.* 68, 214–220.

Ficke, D. R., Thorpe, R., Gordon-Salant, S., and Ferrucci, L. (2011c). Hearing loss prevalence and risk factors among older adults in the United States. *J. Gerontol. A Biol. Sci. Med. Sci.* 66, 582–590. doi: 10.1093/gerona/glr092

Lin, F. R., Vaffe, K., Xia, J., Xue, Q.-L., Harris, T. B.,_purchase-Helzner, E., et al. (2013). Hearing loss and cognitive decline in older adults. *JAMA Intern. Med.* 173, 293–299.

Llano, D. A., Issa, L. K., Devanarayan, P., Devanarayan, V., and Alzheimer’s Disease Neuroimaging Initiative Adni (2020). Hearing loss in Alzheimer’s disease is associated with altered serum lipidomic biomarker profiles. *Cells* 9:2556. doi: 10.3390/cells9122556

McKchnan, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* 34, 939–944. doi: 10.1212/wnl.34.7.939

McLachlan, N. M., and Wilson, S. J. (2017). The contribution of brainstem and cerebellar pathways to auditory recognition. *Front. Psychol.* 8:265. doi: 10.3389/fpsyg.2017.00265

Mertens, G., Andries, E., Claes, A. J., Topsakal, V., Van De Heyning, P., Rompasy, V., et al. (2021). Cognitive improvement after cochlear implantation in older adults with severe or profound hearing impairment: a prospective, longitudinal, controlled, multicenter study. *Ear. Hear.* 42:606. doi: 10.1097/aud.0000000000009962

Nadhimy, I., and Llano, D. A. (2020). Does hearing loss lead to dementia? A review of the literature. *Hear. Res.* 402:108038. doi: 10.1016/j.heares.2020.108038

Nash, S. D., Cruickshanks, K. J., Klein, R., Klein, B. E., Nieto, F. J., Huang, G. H., et al. (2011). The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study. *Arch. Otolaryngol. Head Neck Surg.* 137, 432–439. doi: 10.1001/archoto.2011.15

Panza, F., Sollfrizzo, V., and Logroscino, G. (2015). Age-related hearing impairment—a risk factor and frailty marker for dementia and AD. *Nat. Rev. Neurolog.* 11:166. doi: 10.1038/nrneurol.2015.12

Petrachi, A., Kaernbach, C., Ratnam, R., and Bower, J. M. (2011). Increased activation of the human cerebellum during pitch discrimination: a position emission tomography (PET) study. *Hear. Res.* 282, 35–48. doi: 10.1016/j.heares.2011.09.008

Popelka, M. M., Cruickshanks, K. J., Wiley, T. L., Tweed, T. S., Klein, B. E., and Klein, R. (1998). Low prevalence of hearing aid use among older adults with hearing loss: the Epidemiology of Hearing Loss Study. *J. Am. Geriatr. Soc.* 46, 1075–1078. doi: 10.1111/j.1532-5415.1998.tb06643.x

Proft, O., Škoch, A., Babogová, Z., Tintěra, J., Hlinka, J., and Syka, J. (2014). Diffusion tensor imaging and MR morphometry of the central auditory pathway and auditory cortex in aging. *Neuroscience* 260, 87–97. doi: 10.1016/j.neuroscience.2013.12.010

R Development Core Team (2014). *R: A Language and Environment for Statistical Computing*. Vienna: R Foundation for Statistical Computing.

Ren, F. B., Ma, W., Li, M., Sun, H., Xin, Q., Zong, W., et al. (2018). Gray matter atrophy in neurodegeneration—a meta-analysis. *J. Neuroimaging Psychiatry* 88, 780–788. doi: 10.1136/jnp-2017-315607

Sawilowsky, S. S. (2009). New effect size rules of thumb. *J. Magr. Reson. Imaging* 27, 685–691.

Simic, G., Stanic, G., Mladinov, M., Jovanov et al. (2018). Hearing loss and the risk of dementia in later life. *Maturitas* 103, 2716–2724. doi: 10.1001/archinte.163.22.2716

Tikkinen, K., Tabin, K., Ropponen, T., Soininen, H., and Jylhä, K. (2000). Increased auditory acuity and auditory cortex metabolic activity in the elderly. *Brain Res.* 877, 161–165. doi: 10.1016/S0006-8993(00)01253-8

Tolouei, S., PouiiiTX, N., and Shaker, R. (2018). Effect of hearing loss on brain structure: a comprehensive meta-analysis. *Front. Neurosci.* 12:105. doi: 10.3389/fnins.2018.00105

Tolouei, S., PouiiiTX, N., and Shaker, R. (2018). Effect of hearing loss on brain structure: a comprehensive meta-analysis. *Front. Neurosci.* 12:105. doi: 10.3389/fnins.2018.00105
Snider, R. S., and Stowell, A. (1944). Receiving areas of the tactile, auditory, and visual systems in the cerebellum. *J. Neurophysiol.* 7, 331–357. doi: 10.1152/jn.1944.7.6.331

Swords, G. M., Nguyen, L. T., Mudar, R. A., and Llano, D. A. (2018). Auditory system dysfunction in Alzheimer disease and its prodromal states: a review. *Aging Res. Rev.* 44, 49–59. doi: 10.1016/j.arr.2018.04.001

Thomson, R. S., Auduong, P., Miller, A. T., and Gurgel, R. K. (2017). Hearing loss as a risk factor for dementia: a systematic review. *Laryngoscope Investig. Otolaryngol.* 2, 69–79.

Toniolo, S., Serra, L., Olivito, G., Marra, C., Bozzali, M., and Cercignani, M. (2018). Patterns of cerebellar gray matter atrophy across Alzheimer's disease progression. *Front. Cell. Neurosci.* 12:430. doi: 10.3389/fncel.2018.00430

Utoomprurkporn, N., Woodall, K., Stott, J., Costafreda, S. G., and Bamiou, D. E. (2020). Hearing-impaired population performance and the effect of hearing interventions on Montreal Cognitive Assessment (MoCA): systematic review and meta-analysis. *Int. J. Geriatr. Psychiatry* 35, 962–971. doi: 10.1002/gps.5354

Wang, X., Woody, C., Chizhevsky, V., Gruen, E., and Landeira-Fernandez, J. (1991). The dentate nucleus is a short-latency relay of a primary auditory transmission pathway. *Neuroreport* 2, 361–364. doi: 10.1097/00001756-199107000-00001

Xu, W., Zhang, C., Li, J.-Q., Tan, C.-C., Cao, X.-P., Tan, L., et al. (2019). Age-related hearing loss accelerates cerebrospinal fluid tau levels and brain atrophy: a longitudinal study. *Aging (Albany N. Y.)* 11:3156. doi: 10.18632/aging.101971

**Conflict of Interest:** VD was an employee of Eisai Pharmaceuticals.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Llano, Kwok, Devanarayan and The Alzheimer’s Disease Neuroimaging Initiative (ADNI). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.